{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:07:40Z","timestamp":1792260460913,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001027","name":"Department of Health and Ageing, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jhep.2022.09.011","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T04:11:36Z","timestamp":1663819896000},"page":"260-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["National trends in retreatment of HCV due to reinfection or treatment failure in Australia"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-0200","authenticated-orcid":false,"given":"Joanne M.","family":"Carson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-372X","authenticated-orcid":false,"given":"Sebastiano","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jhep.2022.09.011_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.09.011_bib2","first-page":"1","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","author":"Hajarizadeh","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.09.011_bib3","author":"World Health Organization","year":"20161"},{"issue":"3","key":"10.1016\/j.jhep.2022.09.011_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2022.09.011_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2018.02.003","article-title":"Strategies to reduce hepatitis C virus reinfection in people who inject drugs","volume":"32","author":"Martinello","year":"2018","journal-title":"Infect Dis Clin North America"},{"key":"10.1016\/j.jhep.2022.09.011_bib6","series-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018)","year":"2018"},{"issue":"6","key":"10.1016\/j.jhep.2022.09.011_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jvh.12852","article-title":"Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia","volume":"25","author":"Hajarizadeh","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.09.011_bib8","series-title":"Australasian viral hepatitis elimination conference","article-title":"High efficacy of DAA therapy for chronic HCV in an Australian real-world cohort : the REACH-C study","author":"Yee","year":"2019"},{"key":"10.1016\/j.jhep.2022.09.011_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103422","article-title":"Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort","volume":"96","author":"Carson","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2022.09.011_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Machine Learn"},{"issue":"5","key":"10.1016\/j.jhep.2022.09.011_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1214\/aos\/1013203451","article-title":"Greedy function approximation: a gradient boosting machine","volume":"29","author":"Friedman","year":"2001","journal-title":"Ann Stat"},{"issue":"350","key":"10.1016\/j.jhep.2022.09.011_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/01621459.1975.10479865","article-title":"The predictive sample reuse method with applications","volume":"70","author":"Geisser","year":"1975","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jhep.2022.09.011_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1214\/ss\/1032280214","article-title":"Bootstrap confidence intervals","volume":"11","author":"DiCiccio","year":"1996","journal-title":"Stat Sci"},{"issue":"9 September","key":"10.1016\/j.jhep.2022.09.011_bib14","first-page":"16","article-title":"Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications","author":"Kwon","year":"2021","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.jhep.2022.09.011_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jvh.13175","article-title":"Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection","volume":"26","author":"Read","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.09.011_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103135","article-title":"High HCV cure rates among people who inject drugs and have suboptimal adherence: a patient-centered approach to HCV models of care","volume":"93","author":"Norton","year":"2021","journal-title":"Int J Drug Pol"},{"issue":"9","key":"10.1016\/j.jhep.2022.09.011_bib17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciac231","volume":"75","author":"Amin","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jhep.2022.09.011_bib18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/QAD.0000000000002562","article-title":"Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV","volume":"34","author":"Hosseini-Hooshyar","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2022.09.011_bib19","first-page":"ciac246","article-title":"Hepatitis C virus reinfection following direct-acting antiviral treatment in\u00a0the prison setting: the SToP-C study","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.09.011_bib20","article-title":"Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people who inject drugs","volume":"1\u20139","author":"Cunningham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.09.011_bib21","series-title":"Australia\u2019s welfare 2021 data insights","year":"2021"},{"key":"10.1016\/j.jhep.2022.09.011_bib22","series-title":"Viral hepatitis mapping project","author":"MacLachlan","year":"2020"},{"key":"10.1016\/j.jhep.2022.09.011_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jvh.13705","article-title":"Phillip |, et\u00a0al. Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort","volume":"29","author":"Carson","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.09.011_bib24","article-title":"Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago","volume":"1\u201333","author":"Tatara","year":"2021","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.jhep.2022.09.011_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11096-019-00917-0","article-title":"Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment","volume":"41","author":"Campos Fern\u00e1ndez de Sevilla","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jhep.2022.09.011_bib26","series-title":"Current HIV\/AIDS reports","first-page":"301","article-title":"Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions","volume":"17","author":"Spinelli","year":"2020"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2023.02.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782203118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782203118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T19:59:42Z","timestamp":1681847982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782203118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S016882782203118X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.09.011","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jhep.2023.02.020","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National trends in retreatment of HCV due to reinfection or treatment failure in Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}